Brought to you by 
Mallinckrodt to co-promote Zogenix’s Sumavel DosePro in the US; terminated
03 Jul 2014
Executive Summary
Less than two months after ending its agreement with Astellas Pharma US, pain management company Zogenix Inc. has licensed Mallinckrodt LLC, the pharmaceutical division of Covidien PLC’s Covidien Ltd., exclusive US co-promotion rights to its marketed product Sumavel DosePro (sumatriptan injection) for acute migraine or cluster headache. The deal expires on June 30, 2014, but may be extended by six-month increments.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Mallinckrodt to co-promote Zogenix’s Sumavel DosePro in the US; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice